New Co-Author paper out now in SciTransMed: Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy

Very exciting day to see this amazing work by the lab of Prof.Neil Watkins published in the prestigious Science Translational Medicine Journal. A huge amount of work for a lot of very talented people over many many years went into this study, and hopefully it will result in significant improvements for the treatment of lung […]

Read More New Co-Author paper out now in SciTransMed: Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy

New Co-Author Publication in Gut: CDK4 inhibitors for treatment of Pancreatic Cancer

More great news, we have another co-author publication in the outstanding journal Gut. This fabulous work was pioneered by the very talented Dr Marina Pajic and her group at the Garvan Institute. We were very honoured to be involved in such amazing work. The title of the publication is “Tailored first-line and second-line CDK4-targeting treatment […]

Read More New Co-Author Publication in Gut: CDK4 inhibitors for treatment of Pancreatic Cancer

New Publication in Cell! The Phosphoregulation of Mitosis

We are incredibly excited to announce that our SnapShot is out today in Cell! This snapshot of mitosis collates hundreds of phosphorylation events and directly links them with their regulatory kinases and counterbalancing phosphatases, in both time and space, in a highly innovative ‘circtanglar’ cell layout. More importantly, the static PDF version is accompanied by an […]

Read More New Publication in Cell! The Phosphoregulation of Mitosis

Switching off Cancers Diversity

A defining feature in over 2/3rds of all solid tumours is the continual loss and gain of whole are small parts of chromosomes. This instability, or CIN for short, strongly implicated in tumour initiation, progression, chemoresistance and poor prognosis. CIN is created through failures during mitosis, whereby whole or parts of a chromosome are segregated […]

Read More Switching off Cancers Diversity

New Publication: Clinical Overview of MDM2/X-Targeted Therapies

Great news, we have a new Mini-Review published in Frontiers Oncology entitled “Clinical Overview of MDM2/X-Targeted Therapies“, which is apart of the Research Topic Human tumor-derived p53 mutants: a growing family of oncoproteins Here is a little snippet from the Abstract to wet your appetite! MDM2 and MDMX are the primary negative regulators of p53, which under […]

Read More New Publication: Clinical Overview of MDM2/X-Targeted Therapies